Table 2. Patients in the Development cohort versus Validation cohort, n (% of total patients in each cohort).

	Development cohort			Validation cohort
	No Structural-AKI	Structural-AKI	Total	No Structural-AKI	Structural-AKI	Total
No Functional-AKI	106 (41.7)	38 (15.0)	144 (56.7)	103 (40.7)	41 (16.2)	144 (56.9)
Functional-AKI	45 (17.7)	65 (25.6)	110 (43.3)	46 (18.2)	63 (24.9)	109 (43.1)
Total	151 (59.4)	103 (40.6)	254	149 (58.9)	104 (41.1)	253

Functional-AKI: Plasma creatinine >26.4 µmol/L (0.3 mg/dl) in 48 hours or 50% in 7 days.

Structural-AKI: Urinary NGAL >140 ng/ml.